IQVIA Holdings Inc. Common Stock vs Medpace Holdings Inc — how do they compare? IQVIA Holdings Inc. Common Stock trades at $261.68 (market cap $42.61B), while Medpace Holdings Inc trades at $614.63 (market cap $16.82B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 2.5× Medpace Holdings Inc's market cap, and IQVIA Holdings Inc. Common Stock is more actively traded (988,398 versus 223,093). Which is the better fit depends on your goals — on Pluang, investors hold IQVIA Holdings Inc. Common Stock for 0 Days and Medpace Holdings Inc for 14 Days on average.
| IQV | MEDP | |
|---|---|---|
Market Cap | $42.61B | $16.82B |
Volume | 988,398 | 223,093 |
Sector | Health | Health |
52-Week High | $275.02 | $630.19 |
52-Week Low | $156.66 | $393.42 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $56.77B | $16.44B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →